Dublin, Jan. 13, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/9tnsnk/u_s_glucose) has announced the addition of the "U.S. Glucose Testing Markets" report to their offering.
U.S. glucose testing is undergoing a significant transition, driven by new analytical technologies and developments in diabetes treatment. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, several segments of the market, such as home testing devices for diabetes management and point of care (POC) instruments for use in professional settings, will exhibit strong growth. Direct access testing has emerged as a strong force in the blood glucose testing segment, and non-invasive and minimally-invasive testing now represent major new areas for the application of IVD testing.
This report describes the specific market segments for blood glucose testing and diabetes management in the U.S. market. It reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum, plasma or whole-blood glucose concentrations. Additionally, this study examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor's offices and at-home care locations.
Moreover, it analyzes almost all of the companies known to be marketing, manufacturing or developing glucose testing products for the U.S. market. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position.
Key Topics Covered:
1. Overview
2. Diabetes
3. Market Analysis: Size, Growth, Share and Competitors
4. Glucose Diagnostic and Monitoring Recommendations
5. Glucose Testing Technology Platforms and Consumable Products
6. Glucose Testing Devices on the Market
7. Business Trends in Glucose Testing
8. Technology Trends
9. Company Profiles
Companies Mentioned
- Abaxis, Inc.
- Abbott Laboratories
- ACON Laboratories
- AgaMatrix
- Alere
- Allmedicus
- Amedica Biotech
- A. Menarini Diagnostics
- Apex Biotechnology Corporation
- Arkray
- Bayer
- B. Braun Melsungen
- Beckman Coulter
- Bionime
- Bio-Rad Laboratories, Inc.
- BioTex
- Calisto Medical
- Cambridge Sensors
- DexCom
- Diagnostic Devices/Prodigy Diabetes Care
- DiaSys
- Echo Therapeutics
- Entra Health Systems
- Fora Care
- Freedom Meditech
- Genesis Health Technologies
- GenExel-Sein
- GlucoPlus
- GluMetrics
- GlySens
- GlySure Limited
- Grove Instruments
For more information visit http://www.researchandmarkets.com/research/9tnsnk/u_s_glucose
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Glucose Testing


Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Instagram Outage Disrupts Thousands of U.S. Users
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Washington Post Publisher Will Lewis Steps Down After Layoffs
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 



